Das Medizinportal


Lipidsenker-Behandlung bei Patienten mit sehr hohem kardiovaskulärem Risiko – Ist der Bedarf schon gedeckt?

Harry Hahmann

  1. Hahmann et al: Lipoprotein finding correlated with the severity of angiographically defined coronary heart disease: Are there differences between women and men: European Heart Journal 1988;9:  89.
  2. Cholesterol Treatment Trialists’ Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590. doi:10.1016/S0140-6736(12)60367-5.
  3. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Steen Z. Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk. Circulation. 2008;117:1945-1954.
  4. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) European Heart Journal (2012) 33, 1635–1701.
  5. Nissen  SE,  Nicholls  SJ,  Sipahi  I,  et  al;  ASTEROID  Investigators. Effect of  very high-intensity   statin   therapy   on   regression   of   coronary   atherosclerosis:   the ASTEROID trial. JAMA.2006; 295:1556-1565.
  6. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).Am J Cardiol Bd. 92 (2003) 152-160.
  7. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N EnglJ Med 2015;372:2387-97.
  8. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014;21(4):464-474.
  9. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–934.
  10. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, for the Pro(a)LiFe-Study Group. Lipoprotein Apheresis in Patients with Maximally Tolerated Lipid Lowering Therapy, Lp(a)-Hyperlipoproteinemia and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study. Circulation. published online 09r 20, 2013 http: //circ.ahajournals.org/ content/early/2013/09/20 /CIRCULATIONAHA. 113.002432.
  11. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal (2012) 33, 1635–1701.

Statin-assoziierte Muskelbeschwerden: Mythos oder Wirklichkeit?

Winfried März, Hubert Scharnagl, Ulrich Laufs


  1. Ross, R. Atherosclerosis - an inflammatory disease. The New England journal of medicine 340, 115-126, doi:10.1056/NEJM199901143400207 (1999).
  2. Glass, C. K. & Witztum, J. L. Atherosclerosis. the road ahead. Cell 104, 503–516 (2001).
  3. Chew, D. P. et al. Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes. Heart 96, 1201–1206, doi:10.1136/hrt.2009.184853 (2010).
  4. Chowdhury, R. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. European heart journal 34, 2940–2948, doi:10.1093/eurheartj/eht295 (2013).
  5. Go, A. S. et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
  6. European Association for Cardiovascular Prevention and Rehabilitation et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European heart journal 32, 1769–1818, doi:10.1093/eurheartj/ehr158 (2011).
  7. Perk, J. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European heart journal 33, 1635–1701, doi:10.1093/eurheartj/ehs092 (2012).
  8. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–45, doi:10.1161/01.cir.0000437738.63853.7a (2014).
  9. Cholesterol Treatment Trialists' (CTT) Collaboration et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 385, 1397-1404, doi:10.1016/S0140-6736(14)61368–4 (2015).
  10. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European heart journal 36, 1012-1022, doi:10.1093/eurheartj/ehv043 (2015).
  11. Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Begaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19, 403-414, doi:10.1007/s10557-005-5686-z (2005).
  12. Laufs, U., Rettig-Ewen, V. & Bohm, M. Strategies to improve drug adherence. European heart journal 32, 264-268, doi:10.1093/eurheartj/ehq297 (2011).
  13. Laufs, U. et al. Treatment Options for Statin-Associated Muscle Symptoms. Deutsches Arzteblatt international 112, 748-755, doi:10.3238/arztebl.2015.0748 (2015).
  14. Laufs, U., Scharnagl, H. & März, W. Statin intolerance. Curr. Opîn. Lipidol. in press (2016).
  15. Shalev, V. et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 169, 260–268, doi:10.1001/archinternmed.2008.552 (2009).
  16. Chodick, G. et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 30, 2167–2179, doi:10.1016/j.clinthera.2008.11.012 (2008).
  17. Cohen, J. D., Brinton, E. A., Ito, M. K. & Jacobson, T. A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6, 208–215, doi:10.1016/j.jacl.2012.03.003 (2012).
  18. Jackevicius, C. A., Mamdani, M. & Tu, J. V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288, 462–467 (2002).
  19. Bitzur, R., Cohen, H., Kamari, Y. & Harats, D. Intolerance to statins: mechanisms and management. Diabetes Care 36 Suppl 2, S325–330, doi:10.2337/dcS13–2038 (2013).
  20. Buettner, C., Davis, R. B., Leveille, S. G., Mittleman, M. A. & Mukamal, K. J. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23, 1182–1186, doi:10.1007/s11606-008-0636-7 (2008).
  21. Buettner, C. et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 125, 176–182, doi:10.1016/j.amjmed.2011.08.007 (2012).
  22. Zhang, H. et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158, 526–534, doi:10.7326/0003-4819-158-7-201304020-00004 (2013).
  23. Cholesterol Treatment Trialists Collaborators et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117–125, doi:10.1016/S0140-6736(08)60104-X (2008).
  24. Ganga, H. V., Slim, H. B. & Thompson, P. D. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168, 6–15, doi:10.1016/j.ahj.2014.03.019 (2014).
  25. Heart Protection Study Collaborative, G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22, doi:10.1016/S0140-6736(02)09327-3 (2002).
  26. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788–2797, doi:10.1161/CIRCULATIONAHA.106.624890 (2006).
  27. Newman, C. B. & Tobert, J. A. Statin intolerance: reconciling clinical trials and clinical experience. JAMA 313, 1011–1012, doi:10.1001/jama.2015.1335 (2015).
  28. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine 359, 2195–2207, doi:10.1056/NEJMoa0807646 (2008).
  29. Joy, T. R. et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 160, 301–310, doi:10.7326/M13-1921 (2014).
  30. Parker, B. A. et al. Effect of statins on skeletal muscle function. Circulation 127, 96–103, doi:10.1161/CIRCULATIONAHA.112.136101 (2013).
  31. Abd, T. T. & Jacobson, T. A. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10, 373–387, doi:10.1517/14740338.2011.540568 (2011).
  32. Pasternak, R. C. et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40, 567–572 (2002).
  33. Mampuya, W. M. et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 166, 597–603, doi:10.1016/j.ahj.2013.06.004 (2013).
  34. Sewright, K. A., Clarkson, P. M. & Thompson, P. D. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 9, 389–396 (2007).
  35. McKenney, J. M., Jacobson, T. A. & Guyton, J. R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97, s89–94 (2006).
  36. Mancini, G. B. et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 29, 1553–1568, doi:10.1016/j.cjca.2013.09.023 (2013).
  37. Sullivan, D. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308, 2497–2506, doi:10.1001/jama.2012.25790 (2012).
  38. Cho, L. et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol 37, 131–139, doi:10.1002/clc.22248 (2014).
  39. Moriarty, P. M. et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 8, 554–561, doi:10.1016/j.jacl.2014.09.007 (2014).
  40. Keating, A. J., Campbell, K. B. & Guyton, J. R. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 47, 398–404, doi:10.1345/aph.1R509 (2013).
  41. Stein, E. A. et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 101, 490–496, doi:10.1016/j.amjcard.2007.09.099 (2008).
  42. Goto, Y. [AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]]. Nihon Rinsho 59 Suppl 3, 398–403 (2001).
  43. Law, M. & Rudnicka, A. R. Statin safety: a systematic review. Am J Cardiol 97, 52C-60C, doi:10.1016/j.amjcard.2005.12.010 (2006).
  44. Armitage, J. The safety of statins in clinical practice. Lancet 370, 1781–1790, doi:10.1016/S0140-6736(07)60716-8 (2007).
  45. Madsen, C. S. et al. The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J Pharmacol Exp Ther 324, 576–586, doi:10.1124/jpet.107.131615 (2008).
  46. Mikus, C. R. et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 62, 709–714, doi:10.1016/j.jacc.2013.02.074 (2013).
  47. Naba, H., Kakinuma, C., Ohnishi, S. & Ogihara, T. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem Biophys Res Commun 340, 215–220, doi:10.1016/j.bbrc.2005.11.179 (2006).
  48. Needham, M. & Mastaglia, F. L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 24, 4–15, doi:10.1016/j.nmd.2013.09.011 (2014).
  49. Obayashi, H. et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci 36, 445–452 (2011).
  50. Sidaway, J. et al. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica 39, 90–98, doi:10.1080/00498250802585539 (2009).
  51. Zhang, P., Verity, M. A. & Reue, K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab 20, 267–279, doi:10.1016/j.cmet.2014.05.003 (2014).
  52. Bersot, T. in The Pharmacological Basis of Therapeutics Vol. 12th ed.  (ed Chabner BA Brunton LL, Knollmann BC, eds. Goodman & Gilman’s )  p 877–905 (McGraw-Hill Professional; 12 edition (January 10, 2011), 2011).
  53. Gong, I. Y. & Kim, R. B. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28, 4–18 (2013).
  54. Knauer, M. J. et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circulation research 106, 297–306, doi:10.1161/CIRCRESAHA.109.203596 (2010).
  55. Lamperti, C. et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 62, 1709–1712, doi:10.1001/archneur.62.11.1709 (2005).
  56. Mohaupt, M. G. et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 181, E11-18, doi:10.1503/cmaj.081785 (2009).
  57. Phillips, P. S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137, 581–585 (2002).
  58. Rodrigues, A. C. Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 6, 621–632, doi:10.1517/17425251003713519 (2010).
  59. Sakamoto, K. & Kimura, J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci 123, 289–294 (2013).
  60. Search Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. The New England journal of medicine 359, 789–799, doi:10.1056/NEJMoa0801936 (2008).
  61. Mallinson, J. E., Constantin-Teodosiu, D., Sidaway, J., Westwood, F. R. & Greenhaff, P. L. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 587, 219–230, doi:10.1113/jphysiol.2008.164699 (2009).
  62. Hoffman, E. P. & Nader, G. A. Balancing muscle hypertrophy and atrophy. Nat Med 10, 584–585, doi:10.1038/nm0604-584 (2004).
  63. Gratsianskii, N. A. [Statins as Anti-Inflammatory Agents]. Kardiologiia 41, 14–26 (2001).
  64. Wu, J. S., Buettner, C., Smithline, H., Ngo, L. H. & Greenman, R. L. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 43, 76–81, doi:10.1002/mus.21847 (2011).
  65. Vladutiu, G. D. et al. Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy. Molec Genet Metab 111, 264–265 (2014).
  66. Mangravite, L. M. et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377–380, doi:10.1038/nature12508 (2013).
  67. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16, 873–879, doi:10.1097/01.fpc.0000230416.82349.90 (2006).
  68. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87, 130–133, doi:10.1038/clpt.2009.197 (2010).
  69. Niemi, M., Pasanen, M. K. & Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63, 157–181, doi:10.1124/pr.110.002857 (2011).
  70. Baker, S. K., Vladutiu, G. D., Peltier, W. L., Isackson, P. J. & Tarnopolsky, M. A. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 35, 94–97 (2008).
  71. Carr, D. F. et al. GATM gene variants and statin myopathy risk. Nature 513, E1, doi:10.1038/nature13628 (2014).
  72. DeGorter, M. K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 6, 400–408, doi:10.1161/CIRCGENETICS.113.000099 (2013).
  73. Isackson, P. J. et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve 44, 531–538, doi:10.1002/mus.22115 (2011).
  74. Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L. & Hegele, R. A. Genetic determinants of statin intolerance. Lipids Health Dis 6, 7, doi:10.1186/1476-511X-6-7 (2007).
  75. Ruano, G. et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 218, 451–456, doi:10.1016/j.atherosclerosis.2011.07.007 (2011).
  76. Vladutiu, G. D. et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 104, 167–173, doi:10.1016/j.ymgme.2011.07.001 (2011).
  77. Vladutiu, G. D. et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34, 153–162, doi:10.1002/mus.20567 (2006).
  78. Tonelli, M., Wanner, C. & Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 160, 182, doi:10.7326/M13-2453 (2014).
  79. Rosenson, R. S. et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8, S58–71, doi:10.1016/j.jacl.2014.03.004 (2014).
  80. Ghatak, A., Faheem, O. & Thompson, P. D. The genetics of statin-induced myopathy. Atherosclerosis 210, 337–343, doi:10.1016/j.atherosclerosis.2009.11.033 (2010).
  81. Wilke, R. A. et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92, 112–117, doi:10.1038/clpt.2012.57 (2012).
  82. Wanner, C., Tonelli, M. & Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85, 1303–1309, doi:10.1038/ki.2014.31 (2014).
  83. Cannon, C. P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England journal of medicine, doi:10.1056/NEJMoa1410489 (2015).
  84. Bookstaver, D. A., Burkhalter, N. A. & Hatzigeorgiou, C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 110, 526–529, doi:10.1016/j.amjcard.2012.04.026 (2012).
  85. Caso, G., Kelly, P., McNurlan, M. A. & Lawson, W. E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99, 1409–1412, doi:10.1016/j.amjcard.2006.12.063 (2007).
  86. Fedacko, J. et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 91, 165-170, doi:10.1139/cjpp-2012-0118 (2013).
  87. Glueck, C. J. et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 27, 1683–1690, doi:10.1185/03007995.2011.598144 (2011).
  88. Kurnik, D. et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 77, 36–41, doi:10.1111/j.1365–2265.2011.04321.x (2012).
  89. Michalska-Kasiczak, M. et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 178, 111–116, doi:10.1016/j.ijcard.2014.10.118 (2015).
  90. Pfeifer, M., Begerow, B. & Minne, H. W. Vitamin D and muscle function. Osteoporos Int 13, 187–194, doi:10.1007/s001980200012 (2002).
  91. Riphagen, I. J., van der Veer, E., Muskiet, F. A. & DeJongste, M. J. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 28, 1247–1252, doi:10.1185/03007995.2012.702102 (2012).
  92. Zlatohlavek, L., Vrablik, M., Grauova, B., Motykova, E. & Ceska, R. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett 33 Suppl 2, 98–101 (2012).
  93. Moriarty, P. M. et al. ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm. Late-Breaking Clinical Trial Abstracts and Clinical Science Special Reports Abstracts From the American Heart Association’s Scientific Sessions 2014. Circulation 130, 2108–2109 (2014).
  94. Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England journal of medicine 372, 1489–1499, doi:10.1056/NEJMoa1501031 (2015).
  95. Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England journal of medicine 372, 1500–1509, doi:10.1056/NEJMoa1500858 (2015).
  96. Seidah, N. G., Awan, Z., Chretien, M. & Mbikay, M. PCSK9: a key modulator of cardiovascular health. Circulation research 114, 1022–1036, doi:10.1161/CIRCRESAHA.114.301621 (2014).
  97. Lipinski, M. J. et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European heart journal, doi:10.1093/eurheartj/ehv563 (2015).
  98. Klose, G., Laufs, U., Marz, W. & Windler, E. Familial hypercholesterolemia: developments in diagnosis and treatment. Deutsches Arzteblatt international 111, 523–529, doi:10.3238/arztebl.2014.0523 (2014).
  99. Bundesausschuss, G. Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung. Richtlinie Methoden vertragsärztliche Versorgung, in der Fassung vom 17. Januar 2006, veröffentlicht im Bundesanzeiger 2006 Nr. 48 (S. 1 523), in Kraft getreten am 1. April 2006,  zuletzt geändert am 19. Februar 2015, veröffentlicht im Bundesanzeiger (BAnz AT 15.05.2015 B7), in Kraft getreten am 16. Mai 2015.
  100. Mancini, G. B. et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 27, 635–662, doi:10.1016/j.cjca.2011.05.007 (2011).

Wirkungsweise und Effekte der PCSK9-Inhibitoren

Ulrich Julius


  1. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126(3):314–345.
  2. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36(17):1012–1022.
  3. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34(2):154–156.
  4. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012;53(12):2515–2524.
  5. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354(12):1264–1272.
  6. Abifadel M, Guerin M, Benjannet S, Rabes JP, Le GW, Julia Z, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012;223(2):394–400.
  7. Abifadel M, Bernier L, Dubuc G, Nuel G, Rabes JP, Bonneau J, et al. A PCSK9 variant and familial combined hyperlipidaemia. J Med Genet 2008;45(12):780–786.
  8. Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, et al. Local Effects of Human PCSK9 on the Atherosclerotic Lesion. J Pathol 2015.
  9. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380(9836):29–36.
  10. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129(2):234–243.
  11. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380(9858):2007–2017.
  12. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015;4(6):e001937.
  13. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015;10–2957.
  14. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1500–1509.
  15. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489–1499.
  16. Stoekenbroek RM, Kastelein JJ, Huijgen R. PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med 2015;13(1):258–0503.
  17. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217 Suppl 1:S1–44.
  18. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia. Circulation 2013;128(19):2113–2120.
  19. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63(13):1278–1288.
  20. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372(25):2387–2397.
  21. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs. N Engl J Med 2015.
  22. Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, et al. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. Circ Res 2015;117(8):731–741.
  23. Julius U, Fischer S, Schatz U, Hohenstein B, Bornstein SR. Lipoprotein apheresis: an update. Clin Lipidol 2013;8(6):693–705.

Was gibt es außer PCSK9-Inhibitoren Neues an Lipidsenkern?

Gerald Klose, Thomas Beckenbauer, Stefan Maierhof, Iris van de Loo, Knut W. Spieker


  1. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109–22
  2. Schwartz GG, Olsson AG, Abt M, Ballantyne CM et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089–99.
  3. Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease investor.lilly.com/releasedetail.cfm
  4. Cannon CP ,Shah S, Dansky HS et al. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N Engl J Med 2010; 363:2406–2415
  5. Hovingh GK, Kastelein JJ, van Deventer SJ et al.  Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. TULIP
  6. Freissmuth M, ?Offermanns S und Böhm  S, Kapitel 7 in Pharmakologie und Toxikologie: Von den molekularen Grundlagen zur Pharmakotherapie, Springer Verlag 2012FH
  7. Santos RD, Raal FJ, Catapano AL et al. , Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):689–99
  8. Klose G, Laufs U, März W et al. Familiäre Hypercholesterinämie: Entwicklungen in Diagnostik und Behandlung, Dtsch Arztebl Int 2014; 111(31–32): 523-9)
  9. Gouni-Berthold I und Berthold HK, Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Atheroscler Suppl. 2015 May;18:28-34. doi: 10.1016/j.atherosclerosissup.2015.02.005.
  10. Fachinformation über den über den Fachinfo-Service® www.rote-liste.de
  11. Sacks FM, Stanesa M, Hegele RA, Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med. 2014; 174(3):443–7
  12. Emerging Risk Factors Collaboration, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009 Jul 22;302(4):412–23
  13. Kamstrup PR et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009 Jun 10;301(22):2331–9 9.)
  14. Nordestgaard BG Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844–53).
  15. Tsimikas S, Viney NJ, Hughes SG et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015 ;386(10002):1472–83
  16. Müller N, Schulte D, Türk K et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J. Lipid Res. 2015 56:(5) 1034–1042
  17. Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 2(8):655–66
  18. Nordestgaard BG, Varbo A, Triglycerides and cardiovascular disease. Lancet. 2014  16;384(9943):626–35
  19. Rip J, Nierman MC, Sierts JA, Petersen W et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther. 2005 Nov;16(11):1276–86
  20. Gaudet D1, Méthot J, Déry S, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013 Apr;20(4):361–9
  21. Pressemitteilung Gemeinsamer Bundesausschuss (GBA) vom 16.4.2015  https://www.g-ba.de/institution/presse/pressemitteilungen/572/
  22. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014 Jul 3;371(1):32–41
  23. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014 Jul 3;371(1):22–31 Blood Institute
  24. Gaudet D, Alexander VJ, Baker BF et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015 Jul 30;373(5):438–47

Die Bedeutung einer regulierten Infiltration von Leukozyten für den Heilungsverlauf nach einem Herzinfarkt

Jochen Pöling


  1. Cohn, J.N., R. Ferrari, and N. Sharpe, Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 2000. 35(3): p. 569–82.
  2. Frantz, S., J. Bauersachs, and G. Ertl, Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res, 2009. 81(3): p. 474–81.
  3. Frangogiannis, N.G., Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res, 2004. 53(11): p. 585–95.
  4. Jung, K., et al., Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ Res, 2013. 112(6): p. 891–9.
  5. Nahrendorf, M., et al., The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med, 2007. 204(12): p. 3037–47.
  6. Kubin, T., et al., Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell, 2011. 9(5): p. 420–32.
  7. Lorchner, H., et al., Myocardial healing requires Reg3beta-dependent accumulation of macrophages in the ischemic heart. Nat Med, 2015. 21(4): p. 353–62.
  8. Parikh, A., A.F. Stephan, and E.S. Tzanakakis, Regenerating proteins and their expression, regulation and signaling. Biomol Concepts, 2012. 3(1): p. 57–70.
  9. Frangogiannis, N.G., The reparative function of cardiomyocytes in the infarcted myocardium. Cell Metab, 2015. 21(6): p. 797–8.
  10. Nahrendorf, M., M.J. Pittet, and F.K. Swirski, Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation, 2010. 121(22): p. 2437–45.
  11. Kanzler, I., et al., Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications. Curr Pharm Biotechnol, 2012. 13(1): p. 37–45.
  12. Mullen, L., et al., Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin Drug Deliv, 2014. 11(1): p. 101–10.